The U.S. health care system is undergoing transformative changes in the way that it delivers and pays for care. The […]
In a letter to the Secretary of Health and Human Services, SWHR expressed its concerns about the future status of […]
SWHR sent comments to the Food and Drug Administration (FDA) regarding the agency’s new draft guidance on pre- or post-market […]
SWHR provided comments to the Food and Drug Administration (FDA) on its recently released draft guidance pertaining pregnancy safety study […]
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment […]
SWHR sent letters to the Senate and House subcommittees that oversee funding for the National Institutes of Health (NIH) urging […]
SWHR sent comments to the U.S. Department of Health and Human Services (HHS) in response to the Pain Management Best […]
SWHR developed a set of principles to address diversity within the Patient-Focused Drug Development (PFDD) Program. The PFDD Program, housed […]
SWHR sent a letter to Dr. Diana W. Bianchi, Director of the Eunice Kennedy Shriver National Institute of Child Health […]
In a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, SWHR expressed concern about CMS’ new […]